3Willing AE. Experimental models: help or hindrance[J]. Stroke, 2009,40(3 Suppl):S152-154.
4Fisher M, Feuerstein G, Howells DW, et al. Update of the stroke therapy academic industry, roundtable preclinical recommendations[J]. Stroke,2009,40(6):2244-2250.
5Rother J. Neuroprotection does not work[J].Stroke,2008,39(2): 523-524.
6Gareia JH, Wagner S, Liu KF, et al. Neurological deficit and extent of neuronal necrosis attributable to middle cerebral artery occlusion in rats. Statistical validation[J]. Stroke,1995,26(4): 627-634.
7Clark WM, Lessor NS, Dixon MP, et al. Monofilament intraluminal middle cerebral artery occlusion in the mouse[J]. Neurol res, 1997,19(6):641-648.
8Hua Q, Zhu X, Li P, et al. Refined Qing Kai Ling, traditional Chinese medicinal preparation, reduces ischemic stroke-induced infarct size and neurological deficits and increases expression of endothelial nitric oxide synthase[J]. Biol pharm bull, 2008,31(4):633-637.
9Bederson JB, Pitts LH, Tsuji M, et al. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination[J]. Stroke,1986,17(3):472-476.
10Recoramendations for standards regarding preclinical neuroprotective and restorative drug development[J]. Stroke,1999,30(12): 2752-2758.
